Skip to main content
HTFL logo

HTFL · Heartflow, Inc.

Track HTFL — free
$45.35 +0.72 (+1.61%)
Market Cap
$3.92B
Shares
87.89M
Volume · Nov 20 323.8K Avg daily vol (3M) 1.85M

Price & Indicators

 

Key stats

Close
$44.63
Thu 19 Nov
Open
$46.57
Thu 19 Nov
Average volume, 30 days
1.7M
shares a session
Short interest
5.7M
6.5% of shares · 3.5 days to cover
Day range
$44.37$47.51
Open $46.57 Close $44.63
52-week closing range
$20.49$60.53
Close $44.63 26.3% under the high
Short volume, last session
49%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Aug 2025 to Nov 2026

Up next

Mar 17, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 12
Earnings call
Revenue growth accelerates as 2026 outlook rises

HeartFlow reported third-quarter revenue of $72.9 million, up 57% year-over-year, and raised 2026 revenue guidance to $262 million to $264 million, representing 49% to 50% growth. Non-GAAP gross margin reached 83.8%, and cash flow profitability is expected by mid-2028.

5 source passages
In the third quarter, total revenue was $72.9 million, up 57% year-over-year, with U.S. revenue up 60%, our fastest U.S. growth in 11 quarters. Turning to our updated outlook for 2026, the strength of our third quarter performance and the momentum across both FFRCT and PLAC support a meaningful increase in our full-year expectations. We now expect total revenue of $262 million to $264 million, representing 49% to 50% growth. Third-quarter gross margin reached 83.8%, compared to 76.8% in the third quarter of 2025. Given our continued financial performance, we have increased confidence in achieving cash flow profitability by mid-2028. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 57% as gross margin reached 84%

Heartflow reported revenue of $72.9 million for three months ended September 30, 2026, up 57%, with gross margin at 84% and net loss narrowing to $11.5 million from $50.9 million.

Revenue $72.86M ▲ 57.4% Net loss $11.51M Diluted EPS -$0.13
Read from the MD&A section
3 source passages
Revenue increased $26.6 million, or 57%, to $72.9 million during the three months ended September 30, 2026, compared to $46.3 million during the three months ended September 30, 2025. Gross margin for the three months ended September 30, 2026 increased to 84% as compared to 77% for the three months ended September 30, 2025. Our net loss for the three months ended September 30, 2026 and 2025 was $11.5 million and $50.9 million, respectively, and $54.6 million and $92.4 million for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 12
Current report 8-K
Revenue rises 57% and full-year guidance increases

Heartflow reported third-quarter 2026 revenue of $72.9 million, up 57% year-over-year, and raised 2026 revenue guidance to $262 million to $264 million from $246 million to $250 million; non-GAAP gross margin guidance increased to approximately 82.5% from approximately 82%.

Financial results
5 source passages
today reported financial results for the third quarter ended September 30, 2026. Total revenue of $72.9 million, a 57% increase year-over-year 2026 Annual Guidance Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year) Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82% Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$238.66M
Trailing 12 months
Net income (TTM)
−$79.02M
Trailing 12 months
Revenue growth YoY
+57.4%
Year over year
Operating margin
-33.1%
Trailing 12 months
P / E (TTM)
11.3
Trailing earnings · reciprocal yield 8.9%
FCF yield
-1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$167.74M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+77.7%
Year over year · more shares
Price change (1Y)
+63.9%
Trailing year
Short interest
6.5%
Latest settlement · 3.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Heartflow delivered 57.4% revenue growth, raised full-year revenue and gross-margin guidance, expanded plaque coverage, and increased confidence in mid-2028 cash flow profitability. It nevertheless remained loss-making, with operating expenses above revenue, while fourth-quarter plaque pricing was expected to be flat and the company disclosed commercialization, reimbursement, AI, regulatory, and competitive risks.

Bullish
  • + Third-quarter total revenue grew 57.4% to $72.9 million, with U.S. revenue up 60% to $67.9 million. new
  • + Full-year revenue guidance was raised to $262 million–$264 million, representing 49%–50% growth. new
  • + Full-year non-GAAP gross margin guidance was raised to approximately 82.5%. new
  • + Third-quarter non-GAAP gross margin improved to 83.8% from 76.8% a year earlier. new
  • + Plaque payer coverage increased to approximately 82% of U.S. lives. new
  • + Management increased its confidence in achieving cash flow profitability by mid-2028. new
Bearish
  • − The company remained GAAP operating-loss-making in the third quarter, with a $13.8 million operating loss. new
  • − The company reported a third-quarter GAAP net loss of $11.5 million, or $0.13 per share. new
  • − Third-quarter operating expenses were 103% of revenue, continuing to exceed revenue. new
  • − Plaque pricing is expected to be roughly flat sequentially in the fourth quarter. new
  • − Plaque commercialization remains nascent, while reimbursement shortfalls could negatively affect platform adoption. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg −14%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 60%
mid-range
Momentum
relative strength
Strong
1-month return −19%
trailing
6-month return +44%
trailing
YTD return +53%
this year
Relative strength +50%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $52 › 200d $36 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +84 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.47% of shares out · ▼ -22.4% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
251 holders — near 1-yr high, broad support
Squeeze score 52
elevated · 0–100
Fundamentals
Excellent
Revenue growth +40%
Y/Y
Gross margin 77%
expanding
EPS growth +82%
Y/Y
Free cash flow $-59.0M
Balance sheet $44.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 79%
annualized · 1-yr
Max drawdown −45%
past year
ATR 8.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
full-year 2026
Total revenue Raised $262M – $264M
Aug 13, 2026 $246M – $250M changed to Nov 12, 2026 $262M – $264M
prior FY $176.03M midpoint +49.4% Y/Y
Plaque-specific revenue $36M – $37M
Non-GAAP gross margin Non-GAAP Raised 82.5%
Aug 13, 2026 82% changed to Nov 12, 2026 82.5%
midterm
Non-GAAP gross margin Non-GAAP 85%
Q4
Volume growth 37%
Q1 of next year
Pricing upside at least 10%
2028 timeframe
Gross margins 85%
Previous outlook earlier release · from the Earnings Call filed Aug 13, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP gross margin · midterm 85%
FLAG-specific revenue · full year 2026 $29M – $31M
Gross margin · 2026 82%
Prior guidance period ended · from the Earnings Call filed Mar 18, 2026
Growth year-over-year · Q1 at least 30%
Guided vs delivered · last 1 settled
Total revenue full year 2025
guided $173M – $173.5M
$176.03M Beat +1.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
−14% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
60% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $52 › 200d $36 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +84 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.47% of shares out · ▼ -22.4% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
251 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $20 Now $45 · 60% Range high $61
vs 200-day avg +26% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
annotated CTA images 250M November 12, 2026 —
coronary CTA image acceptance rates 97% November 12, 2026 —
institutions globally 1,800 November 12, 2026 —
Non-GAAP gross margin non-GAAP 83.8% Third Quarter 2026 —
patients 365,000 November 12, 2026 —
patients worldwide 800,000 November 12, 2026 —
Stock-based compensation costs (personnel and related expenses) $4.7M the three months ended September 30, 2026 filing —
studies 200 November 12, 2026 —
The percentage of our U.S. revenue cases attributable to office and clinic-based accounts 36% the three months ended September 30, 2026 filing —
Loss from operations non-GAAP -$22.98M Six Months Ended June 30, 2026 —
Net loss non-GAAP -$18.69M Six Months Ended June 30, 2026 —
Net loss per share, basic and diluted non-GAAP -$0.22 Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HTFL
Heartflow, Inc.
this stock
$3.92B +53.1% +39.9% — 6.5%
VEEV
Veeva Systems Inc
$42.57B +17.8% +28.1% 43.0 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.74B +70.9% +28.2% 34.8 5.8%
TEM
Tempus AI, Inc.
$10.87B +0.9% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
251
% held
84.6%
Net QoQ
-454.1K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
235
View
Short & Settlement
Short Interest Falling
Shares short
5.7M
Days to cover
3.5d
Change
-1.6M sh
View
Short Volume
Short vol %
49%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
2.7K
Value
$129.0K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
35.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$176.0M
Net income (FY)
$-116.8M
EPS diluted
$-3.17
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
15

Heartflow reported revenue of $72.9 million for three months ended September 30, 2026, up 57%, with gross margin at 84% and net loss narrowing to $11.5 million from $50.9 million.

View
Proposed Sales
Value
$262.3K
Shares
5.7K
Filed
Nov 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Heartflow Reports Third Quarter 2…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
HTFL -25.5% -19.5% +44.0% -24.4% +53.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -20.1% -13.2% +49.6% -19.2% +48.1%
Key facts CIK 1464521 CUSIP 42238D107 13F (30d) 239 filings 234 filers Visit website Investor relations